Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.

ABSTRACT:

Background

Metastasis to the bone is one clinically important features of prostate cancer (PCa). Current diagnostic methods cannot predict metastatic PCa at a curable stage of the disease. Identification of metabolic pathways involved in the growth of bone metastases therefore has the potential to improve PCa prognostication as well as therapy.

Methodology/principal findings

Metabolomics was applied for the study of PCa bone metastases (n = 20) in comparison with corresponding normal bone (n = 14), and furthermore of malignant (n = 13) and benign (n = 17) prostate tissue and corresponding plasma samples obtained from patients with (n = 15) and without (n = 13) diagnosed metastases and from men with benign prostate disease (n = 30). This was done using gas chromatography-mass

SUBMITTER: Thysell E 

PROVIDER: S-EPMC2997052 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature